Regulation

Lupus nephritis patients gain oral option as FDA approves Aurinia’s Lupkynis 

Inclusion of dosing program in label could extend patent coverage

FDA’s approval Friday of Lupkynis voclosporin will allow Aurinia to introduce an oral therapy into a new marketplace for drugs to treat lupus nephritis, for which there had